ReviewInternational journal of audiology2018
Chemoradiation-induced hearing loss remains a major concern for head and neck cancer patients.
Review in International journal of audiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 3 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Accelerated vs. conventionally fractionated adjuvant radiotherapy in high-risk head and neck cancer: a meta-analysis.Radiation oncology (London, England) · 2018Pooled it
- Clinical trials, ototoxicity grading scales and the audiologist's role in therapeutic decision making.International journal of audiology · 2018Pooled it
- Ototoxic effects of antineoplastic drugs: a systematic review.Brazilian journal of otorhinolaryngologyPooled it
- Audiometric Monitoring and Its Determinants in Patients Undergoing Chemoradiotherapy for Head and Neck Cancer.Medical sciences (Basel, Switzerland) · 2026Article
- A retrospective audit of audiology encounters in patients undergoing Cisplatin treatment at a large Australian tertiary cancer care centre.Journal of cancer survivorship : research and practice · 2026Article
- Article
- Article
- Trends in ototoxicity monitoring among cisplatin-treated patients with cancer.Journal of cancer survivorship : research and practice · 2025Article
- Survivors' perspectives on cisplatin-induced ototoxicity and barriers to ototoxicity monitoring.Journal of cancer survivorship : research and practice · 2025Article
- Survivorship therapy needs after radiotherapy for head and neck cancer: surveying opportunities for growth (STRONG).Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Chronic inflammation in a radium dial painter cohort: elevated neutrophil to lymphocyte ratio and radiation-induced hearing loss.Journal of radiological protection : official journal of the Society for Radiological Protection · 2025Article
- Article
- Treatment-related hearing loss in weekly versus triweekly cisplatin chemoradiation for head and neck cancer.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2024Article
- The role of genetic variants in the prediction of hearing loss due to cisplatin chemoradiotherapy.Cancer medicine · 2024Article
- A detailed insight of the tumor targeting using nanocarrier drug delivery system.Drug delivery · 2023Review
- Hearing screening and amplifier uptake results in a multidisciplinary head and neck cancer survivorship clinic.Journal of cancer survivorship : research and practice · 2023Article
- Risk factors associated with cisplatin-induced ototoxicity in Japanese patients with solid tumors.Cancer medicine · 2023Article
- Treatment Considerations for Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to Cisplatin.Current treatment options in oncology · 2023Review
- Cisplatin exposure acutely disrupts mitochondrial bioenergetics in the zebrafish lateral-line organ.Hearing research · 2022Article
- Eustachian Tube Functions in Concurrent Chemoradiotherapy for Head and Neck Cancer Patients.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
objectiveReview of the literature regarding hearing loss in patients with head and neck cancer treated with chemoradiation.
designStudies in the literature are reviewed that pertain to hearing loss sustained in head and neck cancer patients receiving cisplatin-based chemoradiation. Personal observations noted while treating these patients are also detailed. STUDY SAMPLE: PubMed was searched for pertinent articles regarding hearing loss in head and neck cancer patients receiving cisplatin chemotherapy and/or radiation.
resultsStudies on the incidence and severity of hearing loss in head and neck cancer patients are limited, but those studies suggest that the risk of hearing loss is greater with higher-dose regimens.
conclusionsNewer cisplatin chemotherapy regimens using lower, weekly doses may be associated with a lower incidence and severity of hearing loss; however, large prospective studies are needed. Such information will be paramount to effective pre-treatment counselling of head and neck cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.